The health minister, Yuli Edelstein, said in an interview Friday that Israel had entered into negotiations with drugmakers as an “early bird,” and that the companies were interested in supplying Israel because of its HMOs’ reputation for efficiency and gathering reliable data. “We are leading the world race thanks to our early preparations,” he said.